Picture loading failed.

Anti-CTLA4 therapeutic antibody (Pre-made Ipilimumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-277-1mg 1mg 3090
GMP-Bios-ab-277-10mg 10mg 21890
GMP-Bios-ab-277-100mg 100mg 148000
GMP-Bios-ab-277-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CTLA4 therapeutic antibody (Pre-made Ipilimumab biosimilar,Whole mAb)
INN Name Ipilimumab
TargetCTLA4
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2005
Year Recommended2006
CompaniesAduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center
Conditions ApprovedMalignant melanoma;Renal cell carcinoma
Conditions ActiveColorectal cancer;Non-small cell lung cancer;Gastric cancer;Glioblastoma;Head and neck cancer;Mesothelioma;Oesophageal cancer;Prostate cancer;Small cell lung cancer;Urogenital cancer;Adrenocortical carcinoma;Breast cancer;CNS cancer;Gastrointestinal cancer;Genitourinary disorders;Gynaecological cancer;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Neuroendocrine tumours;Ovarian cancer;Pancreatic cancer;Penile cancer;Solid tumours;Thyroid cancer;Uveal melanoma;Diffuse large B cell lymphoma;Liver cancer;Lung cancer;Glioma
Conditions DiscontinuedHIV infections;Lymphoma
Development TechMedarex UltiMAb Mouse